FOUNDATIONFOCUS™ CDx BRCA
- Cancer Type
- Sample Type
- Results Expected
What is FoundationFocus CDx BRCA?
FoundationFocus CDx BRCA is the first FDA-approved companion diagnostic assay for Rubraca® (rucaparib), a PARP inhibitor therapy for the treatment of advanced ovarian cancer.
Conventional tests look only for germline alterations in blood or saliva. FoundationFocus CDx BRCA analyzes ovarian cancer tumor tissue to detect both germline (inherited) and somatic (acquired) BRCA1/2 mutation types associated with response to PARP inhibitor therapy.1,2
FoundationFocus CDx BRCA
1 in 4
women with ovarian cancer are BRCA+ (positive)
- First FDA-approved next-generation sequencing (NGS) companion diagnostic for Rubraca®
- Uncovers more BRCA mutations with a single tissue test
- Can help identify more women who may benefit from Rubraca®, a PARP inhibitor therapy, as compared to germline testing alone 2-5